Clinical Trial Detail

NCT ID NCT02057107
Title Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Pittsburgh
Indications

head and neck squamous cell carcinoma

Therapies

Cetuximab

Docetaxel

Age Groups: adult

No variant requirements are available.